Filing Details
- Accession Number:
- 0001144204-10-021075
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-04-19 13:00:00
- Reporting Period:
- 2010-04-16
- Filing Date:
- 2010-04-19
- Accepted Time:
- 2010-04-19 16:22:37
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1318641 | Cleveland Biolabs Inc | CBLI | Services-Commercial Physical & Biological Research (8731) | 200077155 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1370083 | V Andrei Gudkov | 73 High Street Buffalo NY 14203 | Chief Scientific Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2010-04-16 | 200 | $3.59 | 1,514,400 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2010-04-16 | 100 | $3.62 | 1,514,300 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2010-04-16 | 800 | $3.60 | 1,513,500 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2010-04-16 | 3,900 | $3.61 | 1,509,600 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Options (Right to Buy) | $8.36 | 2007-04-06 | 2017-04-05 | 37,500 | 37,500 | Direct |
| Common Stock | Employee Stock Options (Right to Buy) | $4.00 | 2008-02-04 | 2018-02-03 | 137,250 | 174,750 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2017-04-05 | 37,500 | 37,500 | Direct |
| 2018-02-03 | 137,250 | 174,750 | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan and represent approximately 0.3% of the reporting person's 1,549,600 shares held prior to adoption of the plan. The maximum sales subject to the plan in its entirety represent approximately 3.9% of the reporting person's shares held prior to adoption of the plan.
Billionaire Hedge Funds
